Progress in diagnosis and treatment of Kawasaki disease with coronary artery disease in children
-
摘要: 皮肤黏膜淋巴结综合征即川崎病,自1967年日本医生首次报道以来,全世界60多个国家及地区陆续已有相关病例报告,近些年世界各国的发病率也陆续增加。川崎病病因和发病机制至今仍未明确,一般认为川崎病是一种以急性全身血管炎为主要表现的自限性疾病,主要影响中小型动脉,在婴儿和5岁以下儿童多发。目前认为川崎病最严重的并发症是冠状动脉病变,已取代风湿热成为发达国家儿童后天获得性心脏病的主要病因。随着现代医学诊疗技术的发展,大多数川崎病患儿能够及时准确诊断,再加上积极予以丙种球蛋白治疗,因此川崎病合并冠状动脉病变的发病率有所下降,但最终仍有2%~3%的患儿可能发生冠状动脉狭窄、扩张或闭塞,严重者可导致心肌梗死。因此,如何早期识别川崎病,并在川崎病合并冠脉病变时可以及时发现和干预,从而改善患儿生活质量、降低病死率,已成为川崎病诊疗策略中最值得关注并亟待解决的问题。本文就川崎病合并冠状动脉病变的诊断和治疗进行综述,为临床工作的儿科医生以及管理受川崎病影响儿童的社区全科医师在川崎病合并冠状动脉病变的诊断和治疗上提供一定的参考依据。Abstract: Kawasaki disease, or cutaneous mucocutaneous lymph node syndrome, has been reported in more than 60 countries and regions worldwide since it was first reported by doctors in Japan in 1967. Its incidence has been increasing in recent years in countries around the world. The etiology and pathogenesis of Kawasaki disease remain unclear. In general, we can assume that Kawasaki disease is a self-limiting disease with acute systemic vasculitis, mainly affecting small and medium-sized arteries, and it is prevalent in infants and children under 5 years of age. The most serious complication of Kawasaki disease is now coronary artery disease, which has replaced rheumatic fever as the main cause of acquired heart disease in children in developed countries. With the development of modern medical treatment technology, most children with Kawasaki disease can be diagnosed accurately in time. Coupled with active treatment with gammaglobulin, the incidence of Kawasaki disease combined with coronary artery lesions decreased, but eventually 2%-3% of children may still develop coronary artery stenosis, dilatation or occlusion, which can lead to myocardial infarction in severe cases. Therefore, identifying Kawasaki disease at an early stage, and detecting and intervening in Kawasaki disease combined with coronary artery lesions in time, to improve the quality of life of children and reduce the morbidity and mortality rate, has become the most noteworthy and urgent problem in the diagnosis and treatment strategy of Kawasaki disease. This article provides a review of the diagnosis and treatment of Kawasaki disease combined with coronary artery lesions to provide a reference point for pediatricians working in the clinic and for community general practitioners managing children affected by Kawasaki disease in the diagnosis and treatment of Kawasaki disease combined with coronary artery lesions.
-
Key words:
- Kawasaki disease /
- Coronary artery lesions /
- Child /
- Gammaglobulin
-
[1] ELAKABAWI K, LIN J, JIAO F Y, et al. Kawasaki disease: Global burden and genetic background[J]. Cardiol Res, 2020, 11(1): 9-14. doi: 10.14740/cr993 [2] ZHAO Q M, HUANG M, HUANG M R, et al. Characteristics and trends in diagnosis of Kawasaki disease outside the usual age range[J]. Clin Rheumatol, 2021, 40(4): 1515-1523. doi: 10.1007/s10067-020-05361-4 [3] BUTTERS C, CURTIS N, BURGNER D P. Kawasaki disease fact check: Myths, misconceptions and mysteries[J]. J Paediatr Child Health, 2020, 56(9): 1343-1345. doi: 10.1111/jpc.15101 [4] SONI P R, NOVAL R M, ARDITI M. A comprehensive update on Kawasaki disease vasculitis and myocarditis[J]. Curr Rheumatol Rep, 2020, 22(2): 6. doi: 10.1007/s11926-020-0882-1 [5] SOSA T, BROWER L, DIVANOVIC A. Diagnosis and management of Kawasaki disease[J]. JAMA Pediatr, 2019, 173(3): 278-279. doi: 10.1001/jamapediatrics.2018.3307 [6] Research Committee on Kawasaki Disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease[R]. Tokyo: Ministry of Health and Wel-fare, 1984. [7] KUROTOBI S, NAGAL T, KAWAKAMI N, et al. Coronary diameter in normal infants, children and patients with Kawasaki disease[J]. Pediatr Int, 2002, 44(1): 1-4. doi: 10.1046/j.1442-200X.2002.01508.x [8] DE ZORZI A, COLAN S D, GAUVREAU K, et al. Coronary artery dimensions may be misclassified as normal in Kawasaki disease[J]. J Pediatr, 1998, 133(2): 254-258. doi: 10.1016/S0022-3476(98)70229-X [9] NEWBURGER J W, TAKAHASHI M, GERBER M A, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association[J]. Pediatrics, 2004, 114(6): 1708-1733. doi: 10.1542/peds.2004-2182 [10] 王新房, 谢明星. 超声心动图学[M]. 5版. 北京: 人民卫生出版社, 2016: 596-597.WANG X F, XIE M X. Echocardiography[M]. 5th Ed. Beijing: People ' s Medical Publishing House, 2016: 596-597. [11] BROGAN P, BURNS J C, CORNISH J, et al. Lifetime cardiovascular management of patients with previous Kawasaki disease[J]. Heart, 2020, 106(6): 411-420. doi: 10.1136/heartjnl-2019-315925 [12] BURNS J C, EL-SAID H, TREMOULET A H, et al. Management of myocardial infarction in children with giant coronary artery aneurysms after Kawasaki disease[J]. J Pediatr, 2020, 221: 230-234. doi: 10.1016/j.jpeds.2020.02.033 [13] 邓文杰, 周乾潮, 朱滨玉, 等. 小儿川崎病冠状动脉病变的超声诊断价值[J]. 中外医学研究, 2020, 18(14): 60-61. doi: 10.14033/j.cnki.cfmr.2020.14.023DENG W J, ZHOU Q C, ZHU B Y, et al. The value of ultrasound diagnosis of kawasaki disease coronary artery disease in children[J]. Chinese and Foreign Medical Research, 2020, 18(14): 60-61. doi: 10.14033/j.cnki.cfmr.2020.14.023 [14] 冯俊, 李岩, 常凤玲. 小儿川崎病冠状动脉病变的超声诊断及随访[J]. 实用医学影像杂志, 2018, 19(3): 232-234. doi: 10.16106/j.cnki.cn14-1281/r.2018.03.016FENG J, LI Y, CHANG F L. Diagnosis of coronary arterial lesion and follow-up in children with kawasaki disease by echocardiography[J]. Journal of Practical Medical Imaging, 2018, 19(3): 232-234. doi: 10.16106/j.cnki.cn14-1281/r.2018.03.016 [15] 陈治锋. 超声心动图在川崎病冠状动脉病变诊断与随访中的应用效果、价值分析[J]. 首都食品与医药, 2019, 26(23): 110-111. doi: 10.3969/j.issn.1005-8257.2019.23.092CHEN Z F. Application effect and value analysis of echocardiography in diagnosis and follow-up of coronary artery disease in Kawasaki disease[J]. Capital Food Medicine, 2019, 26(23): 110-111. doi: 10.3969/j.issn.1005-8257.2019.23.092 [16] 周乾潮, 金婧, 邓文杰, 等. 超声心动图在川崎病冠状动脉病变诊断中的应用价值研究[J]. 现代医用影像学, 2019, 28(2): 354-355. https://www.cnki.com.cn/Article/CJFDTOTAL-XDYY201902056.htmZHOU Q C, JIN J, DENG W J, et al. Application value of echocardiography in the diagnosis of coronary artery disease in Kawasaki disease[J]. Modern Medical Imageology, 2019, 28(2): 354-355. https://www.cnki.com.cn/Article/CJFDTOTAL-XDYY201902056.htm [17] CAPANNARI T E, DANIELS S R, MEYER R A, et al. Sensitivity, specificity and predictive value of two dimensional echocardiography in detecting coronary artery aneurysms in patients with Kawasaki disease[J]. J Am Coll Cardiol, 1986, 7(2): 355-360. doi: 10.1016/S0735-1097(86)80505-8 [18] 王雷, 夏焙. 超声心动图在川崎病诊断、治疗及长期随访中的应用进展: 2017年AHA指南的解读[J]. 中华医学超声杂志(电子版), 2019, 16(3): 161-165. doi: 10.3877/cma.j.issn.1672-6448.2019.03.001WANG L, XIA P. Application of echocardiography in diagnosis, treatment, and long-term management of Kawasaki disease: Interpretation of the 2017 AHA Guidelines[J]. Chinese Journal of Medical Ultrasound(Electronic Edition), 2019, 16(3): 161-165. doi: 10.3877/cma.j.issn.1672-6448.2019.03.001 [19] 杨小兰, 杨小菊, 蒋红, 等. MSCT与TTE对川崎病冠状动脉瘤中的诊断价值对比研究[J]. 中国CT和MRI杂志, 2019, 17(8): 45-47. https://www.cnki.com.cn/Article/CJFDTOTAL-CTMR201908014.htmYANG X L, YANG X J, JIANG H, et al. Comparison on diagnostic value between MSCT and TTE for coronary aneurysms in Kawasaki disease[J]. Chinese Journal of CT and MRI, 2019, 17(8): 45-47. https://www.cnki.com.cn/Article/CJFDTOTAL-CTMR201908014.htm [20] 骆盼, 李金玲, 柳成良. CT、超声心动图在小儿川崎病冠状动脉病变患者心功能评估中的价值对比[J]. 中国CT和MRI杂志, 2022, 20(1): 85-87. https://www.cnki.com.cn/Article/CJFDTOTAL-CTMR202201026.htmLUO P, LI J L, LIU C L. C omparison on value of CT and echocardiography in the evaluation of cardiac function in children with coronary artery disease of kawasaki disease[J]. Chinese Journal of CT and MRI, 2022, 20(1): 85-87. https://www.cnki.com.cn/Article/CJFDTOTAL-CTMR202201026.htm [21] 张伟, 朱生东, 姚立国. 双源CT在儿童川崎病并发冠心病中的应用价值[J]. 现代医学与健康研究电子杂志, 2019, 3(5): 67-68. https://www.cnki.com.cn/Article/CJFDTOTAL-XYJD201905032.htmZHANG W, ZHU S D, YAO L G. Application value of dual source CT in children with Kawasaki disease complicated with coronary heart disease[J]. Modern Medicine and Health Research, 2019, 3(5): 67-68. https://www.cnki.com.cn/Article/CJFDTOTAL-XYJD201905032.htm [22] 卢小琼, 单光颂, 王本臻, 等. 经胸超声心动图和螺旋CT冠状动脉成像在川崎病冠状动脉病变随访中应用价值的比较[J]. 中国实用儿科杂志, 2021, 36(5): 382-386, 397. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSEK202105015.htmLU X Q, SHAN G S, WANG B Z, et al. Comparison of the value of transthoracic echocardiography and spiral CT coronary angiography in the follow-up of coronary artery lesions of Kawasaki disease[J]. Chinese Journal of Practical Pediatrics, 2021, 36(5): 382-386, 397. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSEK202105015.htm [23] 彭师嘉, 姚剑明, 马献武, 等. 320排CT双低扫描在小儿川崎病冠状动脉造影的应用价值[J]. 影像研究与医学应用, 2020, 4(5): 100-101.PENG S J, YAO J M, MA X W, et al. Application value of 320-slice CT double low scan in coronary angiography in children with Kawasaki disease[J]. Journal of Imaging Research and Medical Applications, 2020, 4(5): 100-101. [24] 顾晓红, 孙爱敏, 王谦, 等. MRI在川崎病冠状动脉和心肌病变评估中的应用[J]. 实用放射学杂志, 2019, 35(5): 798-802.GU X H, SUN A M, WANG Q, et al. Application of MRI inevaluation of coronary artery and myocardial lesions in patients with Kawasaki disease[J]. Journal of Practical Radiology, 2019, 35(5): 798-802. [25] SCHÄFER M, TRUONG U, IVY D D, et al. Children with Kawasaki disease present elevated stiffness of great arteries: Phase-contrast MRI study[J]. J Magn Reson Imaging, 2018, 48(5): 1228-1236. [26] 张静, 郭佑民. 儿童川崎病冠状动脉损害影像学研究进展[J]. 临床医学研究与实践, 2018, 3(18): 192-193. https://www.cnki.com.cn/Article/CJFDTOTAL-YLYS201818090.htmZHANG J, GUO Y M. Imaging research progress of coronary artery lesion in children with Kawasaki disease[J]. Clinical Research and Practice, 2018, 3(18): 192-193. https://www.cnki.com.cn/Article/CJFDTOTAL-YLYS201818090.htm [27] 秦深造. 多层螺旋CT冠状动脉造影的成像技术及临床应用价值[J]. 影像研究与医学应用, 2020, 4(19): 81-82. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYY202019046.htmQIN S Z. Imaging technology and clinical application value of multislice spiral CT coronary angiography[J]. Journal of Imaging Research and Medical Applications, 2020, 4(19): 81-82. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYY202019046.htm [28] 王新芳, 黄先玫, 王跃生, 等. 大剂量丙种球蛋白联合阿司匹林对川崎病患儿血管内皮因子和抵抗素及内脂素的影响[J]. 中华全科医学, 2018, 16(10): 1674-1676. doi: 10.16766/j.cnki.issn.1674-4152.000456WANG X F, HUANG X M, WANG Y S, et al. Effect of high-dose gamma globulin combined aspirin on vascular endothelial factor, resistin and visfatin of children with Kawasaki disease[J]. Chinese Journal of General Practice, 2018, 16(10): 1674-1676. doi: 10.16766/j.cnki.issn.1674-4152.000456 [29] 王华, 张英谦, 李博, 等. 川崎病抗血栓治疗的效果评估及作用机制研究[J]. 中国医药, 2021, 16(11): 1640-1644. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYG202111010.htmWANG H, ZHANG Y Q, LI B, et al. Effect and mechanism of anticoagulant therapy on Kawasaki disease[J]. China Medicine, 2021, 16(11): 1640-1644. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYG202111010.htm [30] 毛英. 川崎病合并冠状动脉病变的研究进展[J]. 世界最新医学信息文摘, 2019, 19(19): 29-30. https://www.cnki.com.cn/Article/CJFDTOTAL-WMIA201919026.htmMAO Y. Advances in research on kawasaki disease with coronary artery disease[J]. World Latest Medicine, 2019, 19(19): 29-30. https://www.cnki.com.cn/Article/CJFDTOTAL-WMIA201919026.htm [31] 柳颐龄, 王献民, 陈婷婷, 等. 氯吡格雷联合阿司匹林对川崎病并发中小型冠状动脉瘤患儿抗血栓治疗的疗效及安全性研究[J]. 中国当代儿科杂志, 2019, 21(8): 801-805. https://www.cnki.com.cn/Article/CJFDTOTAL-DDKZ201908012.htmLIU Y L, WANG X M, CHEN T T, et al. Clinical effect and safety of clopidogrel combined with aspirin in antithrombotic therapy for children with Kawasaki disease complicated by small/medium-sized coronary artery aneurysms[J]. Chinese Journal of Contemporary Pediatrics, 2019, 21(8): 801-805. https://www.cnki.com.cn/Article/CJFDTOTAL-DDKZ201908012.htm [32] 刘芳, 黄国英. 川崎病血管合并症的处理与随访[J]. 中国实用儿科杂志, 2017, 32(8): 579-584. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSEK201708008.htmLIU F, HUANG H Y. Management and follow-up of cardiovascular sequelae in Kawasaki disease[J]. Chinese Journal of Practical Pediatrics, 2017, 32(8): 579-584. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSEK201708008.htm [33] 陈洁. 川崎病合并冠脉瘤抗凝治疗的临床研究[D]. 重庆: 重庆医科大学, 2017.CHEN J. Clinical study of anticoagulant therapy for Kawasaki disease complicated with coronary artery tumor[D]. Chongqing: Chongqing Medical University, 2017. [34] 王祥, 陈智, 肖云彬, 等. 低分子肝素辅助治疗川崎病高凝状态对患儿血管炎症及冠脉损害的改善作用[J]. 儿科药学杂志, 2018, 24(4): 15-17. https://www.cnki.com.cn/Article/CJFDTOTAL-EKYX201804005.htmWANG X, CHEN Z, XIAO Y B, et al. Effect of low molecular weight heparin to vascular inflammation and coronary artery lesion in Kawasaki disease combined with hypercoagulability[J]. Journal of Pediatric Pharmacy, 2018, 24(4): 15-17. https://www.cnki.com.cn/Article/CJFDTOTAL-EKYX201804005.htm [35] 黄惠, 邵会. 低分子肝素钙联合丙种球蛋白对川崎病患儿的安全性与有效性分析[J]. 中国处方药, 2020, 18(4): 70-71. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCF202004039.htmHUAN H, SHAO H. Safety and efficacy of low molecular weight heparin calcium combined with gamma globulin in children with Kawasaki disease[J]. Journal of China Prescription Drug, 2020, 18(4): 70-71. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCF202004039.htm [36] 彭华, 魏培培, 尹薇, 等. 儿童川崎病巨大冠状动脉瘤并血栓形成的临床特征及治疗[J]. 中华实用儿科临床杂志, 2017, 32(21): 1649-1652.PENG H, WEI P P, YIN W, et al. Clinical characteristics and therapy of Kawasaki disease with giant coronary artery and thrombosis[J]. Journal of Applied Clinical Pediatrics, 2017, 32(21): 1649-1652. [37] 隋晓东, 田执梁. 难治性川崎病治疗进展[J]. 儿科药学杂志, 2018, 24(3): 58-62.SUI X D, TIAN Z L. Therapy progress of children with refractory Kawasaki disease[J]. 儿科药学杂志, 2018, 24(3): 58-62. [38] 王晨, 蒋雄刚. 体外循环不停跳冠状动脉旁路移植术临床效果研究进展[J]. 河南医学研究, 2021, 30(13): 2496-2498. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYX202113073.htmWANG C, JIANG X G. Research progress on clinical outcomes of on-pump coronary artery bypass grafting[J]. Henan Medical Research, 2021, 30(13): 2496-2498. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYX202113073.htm [39] 崔青, 沈捷. 川崎病冠状动脉病变的手术治疗[J]. 中华实用儿科临床杂志, 2021, 36(10): 789-793.CUI Q, SHEN J. Surgical treatment of coronary artery lesions caused by Kawasaki disease[J]. Chinese Journal of Applied Clinical Pediatrics, 2021, 36(10): 789-793. [40] TADOKORO N, FUJITA T, FUKUSHIMA S, et al. Multiple coronary artery bypass grafting for Kawasaki disease-associated coronary artery disease[J]. Ann Thorac Surg, 2019, 108(3): 799-805. [41] MCCRINDLE B W, ROWLEY A H, NEWBURGER J W, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American heart association[J]. Circulation, 2017, 135(17): e927-999. [42] 中华医学会儿科学分会心血管学组, 中华儿科杂志编辑委员会. 川崎病冠状动脉病变的临床处理建议(2020年修订版)[J]. 中华儿科杂志, 2020, 58(9): 718-724.Cardiovascular Group, Chinese Society of Pediatrics, Chinese Journal of Pediatrics, Editorial Board. Recommendations for clinical management of Kawasaki disease with coronary artery lesions(2020 revision)[J]. Chinese Journal of Pediatrics, 2020, 58(9): 718-724. [43] JEONG D S, HAN W, LEE Y T, et al. Coronary artery bypass grafting with arterial grafts in patients with Kawasaki disease affecting the coronary artery: A Korean single-center study[J]. J Korean Med Sci, 2018, 33(42): e267. [44] TSUDA E, MIYAZAKI S, YAMADA O, et al. Percutaneous transluminal coronary rotational atherectomy for localized stenosis caused by Kawasaki disease[J]. Pediatr Cardiol, 2006, 27(4): 447-453. [45] JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013)Digest version[J]. Circ J, 2014, 78(10): 2521-2562.
点击查看大图
计量
- 文章访问数: 148
- HTML全文浏览量: 75
- PDF下载量: 10
- 被引次数: 0